Loading…
Legislative Progress
Introduced
February 4, 2026
Latest Action
February 4, 2026
Primary Sponsor
Earl L. "Buddy" CarterRepublican(GA)
Momentum (last 30 days)
2
score
0 actions · 1 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (14)
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Health Issues
Legislation and policies relating to: Potential changes in authorizations for nurse education, workforce, and research programs as a result of workforce reductions and reorganization of agencies and programs within the Department of Health and Human Services Policies related to the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices, child vaccine recommendations and schedule, the Vaccines For Children Program, and the Vaccine Injury Compensation Fund Executive Order, Delivering Gold Standard Childhood Vaccine Recommendations For Americans, and the Department of Health and Human Services request for information, Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making (Docket No. HHS-OS-2026-0332) Cancellation of federal nursing workforce grants Adoption of recommendations of the National Academy of Medicine report, The Future of Nursing 2020-2030: Charting a Path to Achieve Health Equity Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Use of provider-neutral and inclusive language in federal documents, forms, surveys, and legislation, including draft legislation, the Doctors Not AI Act Reauthorization of the Child Nutrition Act Implementation of 42 USC 300gg-5(a) regarding provider non-discrimination by health plans Policies affecting nurse practitioner education and workforce, including pediatric health care workforce shortages Definition, evaluation and enforcement of essential health benefits and provider network adequacy Mental health services and violence prevention, including draft legislation, the Public Safety Mental Health Fellowship Act Childrens online safety and protection of minors using artificial intelligence chatbots Tobacco and vaping prevention and cessation Implementation of provisions of the One Big, Beautiful Bill Act (PL 119-21) H.R. 1435/S. 3714, Family-to-Family Reauthorization Act of 2025 H.R. 1735/S. 779, Early Action and Responsiveness Lifts Youth Minds (EARLY Minds) Act H.R. 2493, Improving Care in Rural America Reauthorization Act of 2025 H.R. 3333, Magnifying Opportunities to Recruit and Educate (MORE) Nurses Act H.R. 3624/S. 1924, Improving Mental Health Access for Students Act H.R. 3701, Family Vaccine Protection Act H.R. 3884/S. 2011, Telemental Health Care Access Act H.R. 4262/S. 4110, Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act H.R. 4340/S. 921, Tyler's Law H.R. 4564, Dillons Law H.R. 4709, Newborn Screening Saves Lives Reauthorization Act of 2025 H.R. 4725, Transparency, Readability, Understandability, Truth, and Helpfulness (TRUTH) in Labeling Act H.R. 5145, Bipartisan Premium Tax Credit Extension Act H.R. 5434/S. 2826, 988 LGBTQ+ Youth Access Act of 2025 H.R. 5469/S. 2858, Stillbirth Health Improvement and Education (SHINE) for Autumn Act H.R. 5582/S. 2355, Patients Deserve Price Tags Act H.R. 6088/S. 3281, Restoring Food Security for Families & Farmers Act of 2025 H.R. 6121/S. 2303, Promoting Physical Activity for Americans Act H.R. 6252, Food Assurance and Security Act H.R. 6396, Kid Providing Resources for Optimal Outcomes against Fatalities (Kid PROOF) Act of 2025 H.R. 6561, PREVENT HPV Cancers Act of 2025 H.R. 6703, Lower Health Care Premiums for All Americans Act H.R. 6844, Tobacco TRACE Act H.R. 6845/S. 3569, S.T.O.P. Illegal Vaping Act H.R. 6945/S. 4242, Supporting Pregnant and Parenting Women and Families Act H.R. 7092/S. 4061, Raising Awareness for Youth Suicide (RAYS) Prevention Act H.R. 7352/S. 4875, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act H.R. 7567, Farm, Food, and National Security Act of 2026 H.R. 7757, Kids Internet and Digital Safety (KIDS) Act H.R. 7867, Infant Formula Safety Modernization Act of 2026 H.R. 7875, Providing Opportunities for Individuals in Need of Treatment and Support (POINTS) Act H.R. 7973/S. 5283, Momnibus Act H.R. 8081/S. 4202, Mental Health Access and Provider Support Act H.R. 8089/S. 4186, Perinatal Workforce Act H.R. 8163/S. 5180, Provider Reimbursement Stability Act H.R. 8201, Expanding Community Access to Health Services Act H.R. 8209, School-Based Health Centers Reauthorization Act of 2026 H.R. 8385, Food Labeling Modernization Act of 2026 H.R. 8425, Strengthening the Vaccines for Children Program Act of 2026 H.R. 8429, Baby Food Safety Act of 2026 H.R. 8521/S. 4387, Protect Moms from Domestic Violence Act H.R. 8657/S. 5305, Campus Lifeline Act H.R. 9257/S. 4754, Primary and Behavioral Health Care Access Act H.R. 9393, Lower Costs, More Transparency Act of 2026 H.R. 10280, 9-8-8 Implementation Act of 2026 S. 272, Protect Infant Formula from Contamination Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836/H.R. 6291, Children and Teens Online Privacy Protection Act (COPPA 2.0) S. 891, Bipartisan Health Care Act S. 1157/H.R. 2319, Women and Lung Cancer Research and Preventive Services Act of 2025 S. 1482/H.R. 4407, National Nursing Workforce Center Act of 2025 S. 1599/H.R. 6394, Midwives for Maximizing Optimal Maternity Services (MOMS) Act of 2025 S. 1748/H.R. 6484, Kids Online Safety Act S. 1874/H.R. 3593, Title VIII Nursing Workforce Reauthorization Act of 2025 S. 2169, Rural Hospital Cybersecurity Enhancement Act S. 2857/H.R. 5448, Protecting Free Vaccines Act S. 2954, Health Care Workforce Expansion Act of 2025 S. 3062/H.R. 8623, Guidelines for User Age-verification and Responsible Dialogue (GUARD) Act of 2025 S. 3199, 988 Lifeline Location Improvement Act of 2025 S. 3315, Health Care Cybersecurity and Resiliency Act of 2025 S. 3386, Health Care Freedom for Patients Act of 2025 S. 3402, Ensuring Excellence in Mental Health Act S. 3799, Healthy Start Reauthorization Act of 2026 S. 3853, End the Vaccine Carveout Act S. 4088, Welcome Back to the Health Care Workforce Act S. 4141, Rural Hospital Revitalization Act S. 4189, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act S. 5090, Digital Age Assurance Act of 2026
Client expense: Not reported · Firm income: $24,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE
2026 · third_quarter · Health Issues
H.R. 6214/S. 2730, Kidney Care Access Protection Act, including provisions related to healthcare and Medicare H.R. 7352/S. 4815, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2026
Client expense: $200,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
FY 2026 Appropriations for Agencies ---Administration for Strategic Preparedness and Response (ASPR) ---Centers for Disease Control and Prevention (CDC) ---Centers for Medicare and Medicaid (CMS) ---Food & Drug Administration (FDA) ---Health Resources and Services Administration (HRSA) ---National Institutes of Health (NIH) FY 2026 Appropriations for Specific Issues ---Alternative Funding Programs ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---CICP ---CMMI: GLOBE and GUARD Models ---Drug Pricing ---Funding for Strategic National Stockpile ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Influenza Planning & Response ---MCM PRV Reauthorization ---Pandemic Preparedness -R&D Funding for Medical Countermeasures ---Pediatric Priority Review Voucher ---Prescription Drug User Fee Act (PDUFA) VIII Implementation ---Project Bioshield ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Section 317 Immunization Program ---Vaccines and Infectious Diseases ---Vaccine Injury Compensation Program 340B Drug Discount Program ---H.R.5256: 340B ACCESS Act ---H.R.9504: Tax Exempt Hospital Transparency Act ---H.R.9599: SECURE 340B Act ---S.5244: SUSTAIN 340B Act ---Program Implementation & Oversight ---Rebate Models Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biodefense Research, Development and Procurement Issues (Non-Funding) ---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research Act) ---Implementation of BIOSECURE Act ---MCM PRV Program Reauthorization ---National Defense Authorization Act 2027 ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Risky Research Review Act ---VICP Loopholes Biosimilars ---H.R.10628/S.5571: Biosimilars Access and Affordability Act ---S.1414: Expedited Access to Biosimilars Act ---S.1954: Biosimilar Red Tape Elimination Act ---Biosimilars Competition (General) ---Interchangeability and Pharmacy Substitution Cell & Gene Therapy ---H.R.1672: Maintaining Investments in New Innovation (MINI) Act Clinical Trial Data in China ---Next-Generation U.S. Clinical Development to Accelerate Cures - Legislative Discussion Draft Data Privacy ---H.R.8413: SECURE Data Act ---Clinical Trial Data in China ---Implementation of BIOSECURE Act Diagnostics and Personalized Medicine Regulation and Oversight Diversity & Inclusion ---H.R.3521: Clinical Trial Modernization Act ---Decentralized Clinical Trials Drug Evaluation and Review ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---FDA Hiring Flexibility Drug Importation Drug Manufacturing, Quality & Distribution ---S.3788: CLEAR Labels Act ---Advanced Manufacturing ---Compounding Pharmacies ---Drug Shortages ---Supply Chain Integrity and Traceability Drug Patenting ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.2658: Medication Affordability and Patient Integrity Act Drug Pricing ---H.R.1492/S.832: Ensuring Pathways to Innovative Cures (EPIC) Act ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.5391/S.2764 Protecting Patient Access to Cancer and Complex Therapies Act ---H.R.9418: Access to Innovative Treatments Act of 2026 ---S.526: Pharmacy Benefit Manager Transparency Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.1954: Biosimilar Red Tape Elimination Act ---S.3014: Ensuring Timely Access to Generics ---CMMI Authority ---Ensuring Access to Generic Medications Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Implementation of ORPHAN Cures Act ---International Pricing Policies ---Tariffs Efforts to Expand the Bioeconomy & Biomanufacturing ---H.R.8930: Federal Biotechnology Workforce Assessment Act ---H.R.8938: Biotechnology Workforce Alignment Act of 2026 Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Generic Drug Entry ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.1095: Stop STALLING Act ---Generic Drug Application Review Reforms ---Incentives for Generic Entry Issues Relating to Medical Research and Animal Testing ---FDA Modernization Act 3.0 Medicaid ---S.526: Pharmacy Benefit Manager Transparency Act ---Alternative Payment Arrangements for Gene Therapies ---Drug Benefit Design ---Most Favored Nation Drug Pricing Proposals ---Pricing and Rebates National Defense ---Medical Countermeasure Priority Review Voucher Reauthorization ---H.R.8800: National Defense Authorization Act for Fiscal Year 2027 National Security ---H.R.10568: Protecting Biological Data as Critical Infrastructure Act ---H.R.10569: Protecting Biotechnology and Biomanufacturing as Critical Infrastructure Act ---S.3741: Biosecurity Modernization and Innovation Act of 2026 ---Clinical Trial Data in China ---CMMI: GLOBE and GUARD Models ---Implementation of BIOSECURE Act ---International Pricing Policies ---Medical Countermeasure Priority Review Voucher Reauthorization ---NSC/OSTP priorities ---Nucleic acid synthesis security and biotechnology governance Opioid Crisis ---Non-Opioid Analgesics Orphan Drug Issues ---H.R.1414: Cameron's Law ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit Pandemic Preparedness ---Drug Supply Chain Management ---R&D Funding for Medical Countermeasures ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Supply Chain Issues Precision Medicine Initiative Rare Pediatric Disease Priority Review ---H.R.10359: Priority for Pediatric Cures Act ---S.822: Scientific EXPERT Act ---Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products ---H.R.5509/S.2903:SAFE STEP Act ---S.864/H.R.6423: HELP Copays Act ---Access to Innovative Treatments ---CMMI Authority ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Medicare Part B Physician-Administered Products ---National Coverage Determination ---Patient Cost-Sharing and Smoothing ---Prior Authorization Reform ---Protected Classes ---Step Therapy ---Support of Patient Premiums and Cost-Sharing Obligations ---Value-Based Contracting and Communications ---Value-Based Purchasing (VBP) Rule Vaccines and Infectious Diseases ---H.R.5509/S.2903: SAFE STEP Act ---H.R.7352/S.4875: PASTEUR Act of 2026 ---H.R.9418: Access to Innovative Treatments Act of 2026 ---H.R.9672: Vaccine Injury Compensation Modernization Act of 2026 ---Adult Immunization ---Maternal Immunization ---MCM Manufacturing & Capacity ---MCM R&D Incentives ---Monoclonal Antibody Coverage and Utilization ---Senate Discussion Draft - Vaccine Injury Protection Act ---Vaccine and Antimicrobial Resistance Product Development and Incentives ---Vaccine Injury Compensation Program ---Vaccine Safety ---Vaccine Safety Net and Vaccine Infrastructure ---Value of Vaccines and Vaccine Confidence
2026 · third_quarter · Medical/Disease Research/Clinical Labs
FY 2026 Appropriations for Agencies ---Administration for Strategic Preparedness and Response (ASPR) ---Biomedical Advanced Research and Development Authority (BARDA) ---Centers for Disease Control and Prevention (CDC) ---Food & Drug Administration (FDA) ---Health Resources and Services Administration (HRSA) ---National Institutes of Health (NIH) FY 2026 Appropriations for Specific Issues ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---Funding for Medical Countermeasures ---Funding for Section 317 ---Funding for Strategic National Stockpile ---Pandemic Preparedness - R&D Funding for Medical Countermeasures ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---VICP/CICP Antimicrobial Resistance ---H.R.7352/S.4875: PASTEUR Act of 2026 Biodefense Research, Development and Procurement Issues ---Medical Countermeasure Priority Review Voucher Reauthorization CDC Reform Pandemic Preparedness ---Medical Countermeasure Priority Review Voucher Reauthorization ---R&D Funding for Medical Countermeasures
Client expense: $2,560,000 · Firm income: Not reported
2026 · third_quarter · Health Issues
H.R. 6214/S. 2730, Kidney Care Access Protection Act, including provisions related to healthcare and Medicare H.R. 7352/S. 4815, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2026
Client expense: $110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medical/Disease Research/Clinical Labs
| Republican |
| TN |
| Chrissy Houlahan | Democratic | PA |
| Christopher H. Smith | Republican | NJ |
| Daniel Meuser | Republican | PA |
| David G. Valadao | Republican | CA |
| Deborah K. Ross | Democratic | NC |
| Don Bacon | Republican | NE |
| Donald G. Davis | Democratic | NC |
| Frank J. Mrvan | Democratic | IN |
| Jake Auchincloss | Democratic | MA |
| Jamie Raskin | Democratic | MD |
| Josh Gottheimer | Democratic | NJ |
| Lori Trahan | Democratic | MA |
| Lucy McBath | Democratic | GA |
| Maria Elvira Salazar | Republican | FL |
| Mariannette Miller-Meeks | Republican | IA |
| Mike Carey | Republican | OH |
| Mike Levin | Democratic | CA |
| Mike Quigley | Democratic | IL |
| Nicholas A. Langworthy | Republican | NY |
| Nikema Williams | Democratic | GA |
| Scott H. Peters | Democratic | CA |
| Suzan K. DelBene | Democratic | WA |
| Terri A. Sewell | Democratic | AL |
| Thomas H. Kean, Jr. | Republican | NJ |
| Yvette D. Clarke | Democratic | NY |
Client expense: $2,560,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS (DRAFT) CLINICAL TRIAL MODERNIZATION ACT; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSION ON FY2027 APPROPRIATIONS; PROVISIONS RELATED TO DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) AND RELATED AGENCIES, FOOD AND DRUG ADMINISTRATION (FDA) AND RELATED AGENCIES, CENTERS FOR DISEASE CONTROL AND PREVENTION AND RELATED AGENCIES, NATIONAL INSTITUTES OF HEALTH (NIH) AND RELATED AGENCIES, OBLIGATE STABLE PACE OF SPENDING FY26 FUNDS GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NATIONAL INSTITUTES OF HEALTH (NIH) RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSION OPPOSING OFFICE OF MANAGEMENT AND BUDGET'S (OMB) PROPOSED RULE, REGULATION FOR FEDERAL FINANCIAL ASSISTANCE (RELEASED 5/29/26) CFF SUBMITS COMMENTS TO ORGAN PROCUREMENT & TRANSPLANT NETWORK (OPTN)/HEALTH RESOURCES & SERVICES ADMINISTRATION (HRSA) IN RESPONSE TO OPTN'S UPDATE ON LUNG CONTINUOUS DISTRIBUTION POLICY PROPOSAL CFF SUBMITS COMMENTS IN RESPONSE TO A REQUEST FOR INFORMATION (RFI) FROM THE FOOD AND DRUG ADMINISTRATION (FDA) ON EXPEDITED INVESTIGATIONAL NEW DRUG PILOT PROGRAM CFF SUBMITS COMMENTS TO DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) IN RESPONSE TO PROPOSED REGULATION ON CLINICAL TRIALS CFF SUBMITS COMMENT TO FOOD AND DRUG ADMINISTRATION (FDA) IN RESPONSE TO DRAFT GUIDANCE ON LEVERAGING PRIOR KNOWLEDGE IN THE DEVELOPMENT OF HUMAN GENE THERAPY PRODUCTS INCORPORATING GENOME EDITING
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
2026 · third_quarter · Health Issues
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS-2454-IFC GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HIGH-DEDUCTIBLE HEALTH PLANS (HDHPs) PAIRED WITH HEALTH SAVINGS ACCOUNTS (HSAs) GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS) GENERAL DISCUSSION ON DRUG PRICING REFORM GENERAL DISCUSSION ON HEALTH COVERAGE REFORM GENERAL DISCUSSIONS ON PHARMACY BENEFIT MANAGERS (PBMs) REFORM INCLUDING TRANSPARENCY AND ACCOUNTABILITY, SPREAD PRICING AND PRICE-LINKED COMPENSATION GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NATIONAL INSTITUTES OF HEALTH (NIH) RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL RECONCILIATION LEGISLATION CFF SUBMITS COMMENTS TO CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) IN RESPONSE TO THEIR REQUEST FOR INFORMATION ON THE AFFORDABLE CARE ACT'S (ACA) ESSENTIAL HEALTH BENEFITS CFF SUBMITS COMMENTS IN RESPONSE TO DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) AND CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) REQUEST FOR INFORMATION ON HOW TO IMPLEMENT PBM MEASURES INCLUDED IN THE LAST CONSOLIDATED APPROPRIATIONS ACT CFF SUBMITS COMMENTS IN RESPONSE TO CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) INTERIM FINAL RULE ON THE MEDICAID WORK REPORTING REQUIREMENTS
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues related to diagnostic testing, Oncology, Hepatitis C funding H.R.7352/S.4875, the Pioneering Antimicrobial Subscriptions To End Upsurging Resistence Act of 2026 (PASTEUR Act) S.1941, the Cure Hepatitis C Act of 2025
Client expense: $310,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
Antimicrobial resistance; advanced molecular detection; national wastewater surveillance system (S.4048 - PREDICT Act); PAMA reform: RESULTS Act (H.R. 5269 S.2761); PASTEUR Act (H.R. 7352 and S. 4875); SUPER BUGS Act (H.R. 7879), and Stop Superbugs Act (S.5237).
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
H.R. 1, One Big Beautiful Bill Act, implementation and patient access issues. S. 1816/H.R. 3514, Improving Seniors' Timely Access to Care Act. S. 1717/H.R. 5343, Ensuring Patient Access to Critical Breakthrough Products Act. H.R. 3521/S. 4440, Clinical Trial Modernization Act. S. 2903/H.R. 5509, Safe Step Act. FY 2027 Labor, HHS, Education appropriations for programs affecting people with chronic diseases and disabilities. S. 494/ H.R.1189 National Plan for Epilepsy Act Senate Finance Committee RFI on Drug Pricing and Health Coverage H.R. 9599 SECURE 340B Act Discussion Draft - 340B Drug Pricing Integrity and Affordability for Patients Act S. 5244 SUSTAIN 340B Act H.R.7352/S. 4875 PASTEUR Act S.3267/H.R. 6130 ASAP Act
Client expense: $21,227 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.3251/S 4440 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -End Coverage with Evidence Development for Alzheimer's medications and Trans Catheter Aortic Valve Replacement -Update CMS Long stay antipsychotic Quality measure -Update FDA Antipsychotic black box warning -Funding for NIH (HR 9260) -PASTEUR Act (HR 7352/S 4975) -Biosimilar Access and Affordability Act (HR10628/S5571) -CMS Fixed Dose Combination Therapies proposed policy -OMB Proposed Uniform Guidance on Federal Grantmaking (HR 6500) -Alzheimer's Early Detection Act (HR 9823) -CMS reporting requirements for Medicare Prescription Payment Program (HR 9260) -CMS Trans Catheter Aortic Valve Replacement NCD proposal
Client expense: $65,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
S. 380/H.R. 1254 - Rural Obstetrics Readiness Act S. 4875/H.R. 7352 - PASTEUR Act of 2026 Reauthorization of the Pandemic and All-Hazards Preparedness Act Tobacco Control Public Health Infrastructure Healthy People 2030 Objectives Chronic Disease of Addiction Federal Vaccine Recommendations Physician Fee Schedule
Client expense: $45,745 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Medical/Disease Research/Clinical Labs
Legislation related to anti-microbial resistance generally Infectious diseases physician work force issues generally H.R.7352 and S. 4875 (PASTEUR Act of 2026), entire bill
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues related to point of care testing and digital pathology; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to infectious disease diagnostics.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
S. 5237, Stop Superbugs Act, Issues pertaining to NIAID grantmaking for antibiotic-resistant infection research. H.R. 7352, S. 4875, PASTEUR Act, Issues pertaining to antimicrobial drug development. H.R. 766, SEWER Act, Issues pertaining to CDC wastewater surveillance activities. S. 4048, PREDICT Act, Issues pertaining to CDC wastewater surveillance activities.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (H.R.7352/S.4875 119th Congress),Administration Executive Orders regarding HHS, NIH, HRSA, FDA, and CDC, Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act (119th Congress, H.R. 4445/S.4283), SUPERBUGS Act, H.R.7879, 119th Congress.
Client expense: $290,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2026 · second_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); P, Infectious diseases and bio-preparedness health professionals loan repayment issues, ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu outbreak (generally, no specific bill), Administration executive orders regarding HHS, NIH, CDC, HRSA, FDA, and USAID FY2026, H.R. 4445/S.4283 Bio-Preparedness Workforce Pilot Program/Public Health Loan Repayment reauthorization legislation, J-1 Visa and Conrad 30 issues, H-1B Visa issues, 2026 CMS practice expense final rule, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR)(H.R. 7352/S.4875, upcoming legislation on CMS practice expense cuts, 2027 CMS Medicare Physician Fee Schedule proposed rule, H.R. 9693, Patients First Act
Client expense: $290,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2026 · second_quarter · Health Issues
H.R. 6214/S. 2730, Kidney Care Access Protection Act, including provisions related to healthcare and Medicare H.R. 7352/S. 4815, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2026
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSION ON FY2027 APPROPRIATIONS; ISSUES RELATED TO HHS AND RELATED AGENCIES, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, OBLIGATE STABLE PACE OF SPENDING FY26 FUNDS GENERAL DISCUSSION OPPOSING OMBS PROPOSED RULE, REGULATION FOR FEDERAL FINANCIAL ASSISTANCE, RELEASED 5/29 FOLLOW UP ON ALTERNATIVE FUNDING PROGRAMS AND IMPORTATION OF DRUGS; CFF SENDS LETTER TO FDA AND CDER REGARDING A CITIZEN PETITION CONCERNING ALTERNATIVE FUNDING PROGRAMS (AFPS) COMMENTS ON DRAFT GUIDANCE FOR THE PLAUSIBLE MECHANISM FRAMEWORK; CFF SUBMITS COMMENTS TO THE FDA ON DRAFT GUIDANCE FOR THE PLAUSIBLE MECHANISM FRAMEWORK, URGING A FLEXIBLE APPROACH TO SUPPORT THE DEVELOPMENT OF GENE EDITING AND OTHER THERAPIES FOR PEOPLE WITH ULTRA-RARE MUTATIONS
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R. 6837: TO AMEND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 TO ENSURE THAT PHARMACY BENEFIT MANAGERS ARE CONSIDERED FIDUCIARIES, AND FOR OTHER PURPOSES; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS H.R. 7895: PBM KICKBACK PROHIBITION ACT; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 3549: PBM FIDUCIARY ACCOUNTABILITY, INTEGRITY, AND REFORM (FAIR) ACT S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS IFR ON 6/1 GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HDHPS PAIRED WITH HSAS GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS) GENERAL DISCUSSION ON DRUG PRICING REFORM GENERAL DISCUSSION ON HEALTH COVERAGE REFORM GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION CFF COMMENTS ON PRIOR AUTHORIZATION PROPOSED RULE; CFF SUBMITS COMMENTS FOR A PROPOSED RULE ON INTEROPERABILITY AND PRIOR AUTHORIZATION FOR DRUGS AND RELATED RFIS PPC STATEMENT IN RESPONSE TO CMS WORK REPORTING RULE; CFF JOINS PATIENT AND HEALTH GROUPS IN STATEMENT EXPRESSING CONCERN ABOUT THE CMS INTERIM FINAL RULE ON THE MEDICAID WORK CFF SENDS COMMENTS TO DOL ON PBM RULE; CFF SUBMITS COMMENTS TO DOL ON THEIR PROPOSED RULE TO IMPROVE TRANSPARENCY OF PHARMACY BENEFIT MANAGERS
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
2026 · second_quarter · Health Issues
Issues related to diagnostic testing, Oncology, Hepatitis C funding H.R.7352/S.4875, the Pioneering Antimicrobial Subscriptions To End Upsurging Resistence Act of 2026 (PASTEUR Act) S.1941, the Cure Hepatitis C Act of 2025
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Health Issues
Issues related to point of care testing and digital pathology; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medicare/Medicaid
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
Legislation related to anti-microbial resistance generally Infectious diseases physician work force issues generally H.R.7352 and S. 4875 (PASTEUR Act of 2026), entire bill
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Antimicrobial resistance; advanced molecular detection; national wastewater surveillance system (S.4048 - PREDICT Act); PAMA reform: RESULTS Act (H.R. 5269 S.2761); PASTEUR Act (H.R. 7352 and S. 4875); SUPER BUGS Act (H.R. 7879).
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
* On April 3, 2026, ADLM wrote a letter endorsing H.R.7352, the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act or PASTEUR Act, which would establish a new federal initiative to incentivize the development and judicious use of antibiotics to combat the increasing number of drug resistant infections.
Client expense: $120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2026 · first_quarter · Health Issues
H.R. 6214/S. 2730, Kidney Care Access Protection Act, including provisions related to healthcare and Medicare H.R. 7352/S. 4815, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2026
Client expense: $380,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (H.R.7352 119th Congress) Senate PASTEUR Act not yet introduced in 119th Congress, Administration Executive Orders regarding HHS, NIH, HRSA, FDA, and CDC, Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act (119th Congress, H.R. 4445)not yet introduced in Senate, SUPERBUGS Act, H.R.7879, 119th Congress.
Client expense: $169,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2026 · first_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); P, Infectious diseases and bio-preparedness health professionals loan repayment issues, ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu outbreak (generally, no specific bill), Administration executive orders regarding HHS, NIH, CDC, HRSA, FDA, and USAID FY2026, H.R. 4445 Bio-Preparedness Workforce Pilot Program/Public Health Loan Repayment reauthorization legislation, J-1 Visa and Conrad 30 issues, H-1B Visa issues, reintroduction of the PASTEUR Act, CMS practice expense final rule, draft legislation to carve out ID physicians from CMS practice expense final rule, ioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR)(H.R. 7352, not yet introduced in the Senate, upcoming legislation on CMS practice expense cuts.
Client expense: $169,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2026 · first_quarter · Health Issues
Issues related to diagnostic testing, Oncology, Hepatitis C funding H.R.7352, the Pioneering Antimicrobial Subscriptions To End Upsurging Resistence Act of 2026 (PASTEUR Act) S.1941, the Cure Hepatitis C Act of 2025
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · first_quarter · Medical/Disease Research/Clinical Labs
H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS SURROUNDING FY2026 APPROPRIATIONS; PROVISIONS RELATED TO FUNDING FOR DOMESTIC AND GLOBAL AMR PROGRAMS, PUBLIC HEALTH WORKFORCE REPAYMENT PROGRAM, BIO-PREPAREDNESS WORKFORCE PILOT PROGRAM, AND PROTECTION OF MEDICARE, MEDICAID, AND SOCIAL SECURITY PROGRAMS. HHS AND RELATED AGENCIES STAFFING AND FUNDING, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, FUNDING FOR NUTRITION ASSISTANCE PROGRAMS, AND MEDICAL EXPENSE DEDUCTION. POLICY RIDERS INCLUDED IN A DRAFT LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION RELATED AGENCIES FUNDING BILL GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS SURROUNDING FY2027 APPROPRIATIONS; PROVISIONS RELATED TO NATIONAL INSTITUTE OF HEALTH AND FOOD AND DRUG ADMINISTRATION CYSTIC FIBROSIS FOUNDATION SENDS LETTER TO CENTERS FOR MEDICARE & MEDICAID SERVICES AND CENTER FOR MEDICARE AND MEDICAID INNOVATION; CYSTIC FIBROSIS FOUNDATION SUBMITS COMMENTS TO CMS/CMMI IN RESPONSE TO A PROPOSED MODEL TO ADDRESS DRUG PRICES IN MEDICARE
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING THE ENHANCED ADVANCED PREMIUM TAX CREDIT EXPIRATION AND EXTENSION GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HEALTH DEDUCTIBLE HEALTH PLANS PAIRED WITH HEALTH SPENDING ACCOUNTS GENERAL DISCUSSIONS SURROUNDING FY2026 APPROPRIATIONS; PROVISIONS RELATED TO FUNDING FOR DOMESTIC AND GLOBAL AMR PROGRAMS, PUBLIC HEALTH WORKFORCE REPAYMENT PROGRAM, BIO-PREPAREDNESS WORKFORCE PILOT PROGRAM, AND PROTECTION OF MEDICARE, MEDICAID, AND SOCIAL SECURITY PROGRAMS. HHS AND RELATED AGENCIES STAFFING AND FUNDING, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, FUNDING FOR NUTRITION ASSISTANCE PROGRAMS, AND MEDICAL EXPENSE DEDUCTION. POLICY RIDERS INCLUDED IN A DRAFT LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION RELATED AGENCIES FUNDING BILL GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH PPC 2027 NOTICE OF BENEFIT AND PAYMENT PARAMETERS; CYSTIC FIBROSIS FOUNDATION JOINS PATIENT AND HEALTH GROUPS IN COMMENTS ON 2027 HHS NOTICE OF BENEFIT AND PAYMENT PARAMETERS PPC LETTER TO CENTERS FOR MEDICARE & MEDICAID SERVICES ON H.R. 1 IMPLEMENTATION; CYSTIC FIBROSIS FOUNDATION JOINS PATIENT AND HEALTH GROUPS IN LETTER TO CMS EXPRESSING CONCERNS AND ASKING FOR FURTHER CLARIFICATION ON PIECES OF H.R. 1 IMPLEMENTATION CYSTIC FIBROSIS FOUNDATION SENDS LETTER TO CENTERS FOR MEDICARE & MEDICAID SERVICES AND CENTER FOR MEDICARE AND MEDICAID INNOVATION; CYSTIC FIBROSIS FOUNDATION SUBMITS COMMENTS TO CMS/CMMI IN RESPONSE TO A PROPOSED MODEL TO ADDRESS DRUG PRICES IN MEDICARE
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · first_quarter · Medicare/Medicaid
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Issues related to point of care testing; Issues related to H.R. 7352 - PASTEUR Act of 2026.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medical/Disease Research/Clinical Labs
Legislation related to anti-microbial resistance generally Infectious diseases physician work force issues generally H.R.7352 (PASTEUR Act of 2026), entire bill
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE